|
CN107164330A
(zh)
|
2011-04-08 |
2017-09-15 |
贝勒医学院 |
使用嵌合细胞因子受体逆转肿瘤微环境的影响
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
WO2013126712A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
EA033110B1
(ru)
|
2012-04-11 |
2019-08-30 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
|
|
US20130280220A1
(en)
*
|
2012-04-20 |
2013-10-24 |
Nabil Ahmed |
Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
|
|
KR20150029714A
(ko)
*
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
|
|
CA2881981A1
(en)
*
|
2012-08-20 |
2014-02-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
|
US20140274801A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified t cells
|
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
CN115028735A
(zh)
*
|
2013-05-03 |
2022-09-09 |
俄亥俄州创新基金会 |
Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
|
|
CA2954168C
(en)
|
2013-08-02 |
2023-09-19 |
The Regents Of The University Of California |
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
|
|
KR102339240B1
(ko)
|
2013-10-15 |
2021-12-15 |
더 스크립스 리서치 인스티튜트 |
펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
|
|
EP3057991B8
(en)
*
|
2013-10-15 |
2019-09-04 |
The Scripps Research Institute |
Chimeric antigen receptor t cell switches and uses thereof
|
|
MX389160B
(es)
*
|
2013-10-31 |
2025-03-20 |
Hutchinson Fred Cancer Res |
Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas.
|
|
US20160296562A1
(en)
*
|
2013-11-21 |
2016-10-13 |
Ucl Business Plc |
Cell
|
|
JP6943568B2
(ja)
|
2013-12-06 |
2021-10-06 |
アメリカ合衆国 |
胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法
|
|
CN113354744A
(zh)
*
|
2013-12-20 |
2021-09-07 |
弗雷德哈钦森癌症研究中心 |
带标签的嵌合效应分子及其受体
|
|
WO2015092024A2
(en)
*
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
US20160333108A1
(en)
*
|
2014-01-13 |
2016-11-17 |
Stephen J. Forman |
CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE
|
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
|
CN106459990B
(zh)
*
|
2014-02-07 |
2021-06-01 |
麦克马斯特大学 |
三功能t细胞抗原偶联物及其制备方法和用途
|
|
US10196608B2
(en)
*
|
2014-02-21 |
2019-02-05 |
Cellectis |
Method for in situ inhibition of regulatory T cells
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
CA2943008C
(en)
*
|
2014-03-19 |
2021-03-30 |
Cellectis |
Cd123 specific chimeric antigen receptors for cancer immunotherapy
|
|
CN104974261B
(zh)
*
|
2014-04-01 |
2019-06-14 |
三生国健药业（上海）股份有限公司 |
重组抗her2/ps双特异性抗体、其制备方法和应用
|
|
EP3126390B2
(en)
*
|
2014-04-03 |
2026-01-07 |
Cellectis |
Cd33 specific chimeric antigen receptors for cancer immunotherapy
|
|
CA2945320A1
(en)
|
2014-04-10 |
2015-10-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Drug regulated transgene expression
|
|
KR20160145802A
(ko)
*
|
2014-04-23 |
2016-12-20 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
|
|
RU2763795C2
(ru)
*
|
2014-04-23 |
2022-01-11 |
Джуно Терапьютикс, Инк. |
Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
|
|
US9975960B2
(en)
|
2014-05-09 |
2018-05-22 |
Samsung Electronics Co., Ltd. |
Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
|
|
JP6682509B2
(ja)
*
|
2014-05-14 |
2020-04-15 |
カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ |
キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
|
|
US11041021B2
(en)
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
|
MX383150B
(es)
*
|
2014-06-02 |
2025-03-13 |
Us Health |
Receptores quiméricos de antígeno que tienen como diana a cd-19.
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
EP3169703B2
(en)
|
2014-07-16 |
2023-12-13 |
Hinrich Abken |
Chimeric antigen receptor and its use
|
|
KR20170037625A
(ko)
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
KR102048855B1
(ko)
|
2014-07-29 |
2019-11-26 |
셀렉티스 |
암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
|
|
JP2017522893A
(ja)
*
|
2014-07-31 |
2017-08-17 |
セレクティスＣｅｌｌｅｃｔｉｓ |
Ｒｏｒ１特異的多重鎖キメラ抗原受容体
|
|
WO2016025454A2
(en)
*
|
2014-08-12 |
2016-02-18 |
Anthrogenesis Corporation |
Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
WO2016033331A1
(en)
*
|
2014-08-28 |
2016-03-03 |
Bioatla, Llc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
WO2016036916A1
(en)
*
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
ES2777305T5
(en)
*
|
2014-09-04 |
2025-09-30 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
CN107002084B
(zh)
*
|
2014-09-19 |
2021-09-10 |
希望之城公司 |
靶向IL13Rα2的共刺激嵌合抗原受体T细胞
|
|
MY167722A
(en)
*
|
2014-10-09 |
2018-09-21 |
Univ Yamaguchi |
Car expression vector and car-expressing t cells
|
|
MA41538A
(fr)
*
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
|
BR112017008042A2
(pt)
|
2014-10-20 |
2017-12-26 |
Juno Therapeutics Inc |
métodos e composições para dosagem em terapia de célula adotiva
|
|
CN107106609A
(zh)
|
2014-10-31 |
2017-08-29 |
宾夕法尼亚大学董事会 |
刺激和扩展t细胞的组合物和方法
|
|
JP7372728B2
(ja)
*
|
2014-10-31 |
2023-11-01 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
改変ｔ細胞に関する方法および組成物
|
|
CN107109438B
(zh)
|
2014-11-05 |
2021-09-03 |
朱诺治疗学股份有限公司 |
用于转导及细胞处理的方法
|
|
AR102417A1
(es)
*
|
2014-11-05 |
2017-03-01 |
Lilly Co Eli |
Anticuerpos biespecíficos anti-tnf- / anti-il-23
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
CA2969456A1
(en)
|
2014-12-03 |
2016-06-09 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
|
BR112017011893A2
(pt)
*
|
2014-12-05 |
2018-07-24 |
City Of Hope |
células t modificadas no receptor de antígeno quimérico direcionado para cs1
|
|
EP4400516A1
(en)
|
2014-12-15 |
2024-07-17 |
The Regents of the University of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
|
EP3234120B1
(en)
|
2014-12-15 |
2025-09-03 |
The Regents of the University of California |
Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
|
|
BR112017013176A2
(en)
*
|
2014-12-19 |
2018-05-15 |
Dana-Farber Cancer Institute Inc. |
chimeric antigen receptors and methods for using them
|
|
KR102376244B1
(ko)
|
2014-12-24 |
2022-03-21 |
오토러스 리미티드 |
세포
|
|
US20180021378A1
(en)
*
|
2014-12-31 |
2018-01-25 |
Anthrogenesis Corporation |
Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
|
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
|
JP6865688B2
(ja)
|
2015-01-16 |
2021-04-28 |
ジュノー セラピューティクス インコーポレイテッド |
Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
|
|
JP7264592B2
(ja)
|
2015-01-26 |
2023-04-25 |
ザ ユニバーシティー オブ シカゴ |
ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
|
|
ES2869972T3
(es)
|
2015-01-26 |
2021-10-26 |
Cellectis |
Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
|
|
WO2016123143A1
(en)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
CN105985444B
(zh)
*
|
2015-02-05 |
2024-02-13 |
博生吉安科细胞技术有限公司 |
一种嵌合抗原受体、以及快速构建嵌合抗原受体的方法及应用
|
|
EP3256492A4
(en)
|
2015-02-09 |
2018-07-11 |
University of Florida Research Foundation, Inc. |
Bi-specific chimeric antigen receptor and uses thereof
|
|
WO2016134284A1
(en)
|
2015-02-19 |
2016-08-25 |
University Of Florida Research Foundation, Inc. |
Chimeric antigen receptors and uses thereof
|
|
CN107530424A
(zh)
|
2015-02-20 |
2018-01-02 |
俄亥俄州国家创新基金会 |
针对nkg2d和肿瘤相关抗原的二价抗体
|
|
EP3804741A3
(en)
*
|
2015-02-24 |
2021-07-14 |
Board of Regents, The University of Texas System |
Selection methods for genetically-modified t cells
|
|
JP7237449B2
(ja)
*
|
2015-02-27 |
2023-03-13 |
アイセル・ジーン・セラピューティクス・エルエルシー |
血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
KR102133857B1
(ko)
*
|
2015-03-02 |
2020-07-20 |
이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 |
Ｐｄ－ｌ１에 의해 유도된 면역관용의 감소
|
|
CA2978186A1
(en)
*
|
2015-03-05 |
2016-09-09 |
Fred Hutchinson Cancer Research Center |
Immunomodulatory fusion proteins and uses thereof
|
|
US10738116B2
(en)
*
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
|
WO2016154621A1
(en)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
|
EA039192B1
(ru)
*
|
2015-03-30 |
2021-12-16 |
Селджин Корпорейшн |
Способ лечения рака и набор для лечения рака
|
|
AU2016246457B2
(en)
|
2015-04-06 |
2020-10-15 |
Cytoimmune Therapeutics, Inc. |
EGFR-directed car therapy for glioblastoma
|
|
MX2017012939A
(es)
*
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
WO2016168773A2
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
|
EP3286225B1
(en)
*
|
2015-04-23 |
2020-07-01 |
Baylor College of Medicine |
Cd5 chimeric antigen receptor for adoptive t cell therapy
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
PT3294764T
(pt)
*
|
2015-05-15 |
2021-02-15 |
Hope City |
Composições de recetores de antigénios quiméricos
|
|
CN108137669B
(zh)
*
|
2015-05-18 |
2023-02-17 |
优瑞科生物技术公司 |
抗ror1嵌合抗原受体
|
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
US10752670B2
(en)
*
|
2015-05-20 |
2020-08-25 |
Cellectis |
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
|
|
CA2986755A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
JP6949728B2
(ja)
|
2015-05-29 |
2021-10-13 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法
|
|
TWI833684B
(zh)
*
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體（ｃａｒ）、組合物及其使用方法
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
WO2016210447A1
(en)
*
|
2015-06-26 |
2016-12-29 |
University Of Southern California |
Masking chimeric antigen receptor t cells for tumor-specific activation
|
|
EP3322801A1
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
EP3328994A4
(en)
*
|
2015-07-31 |
2019-04-17 |
Memorial Sloan-Kettering Cancer Center |
CD56-Faced Antigen-Binding Proteins and Uses Thereof
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
WO2017027291A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
|
CN105384825B
(zh)
*
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
KR20240149974A
(ko)
|
2015-08-11 |
2024-10-15 |
고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 |
항체
|
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
CN108243607A
(zh)
|
2015-09-09 |
2018-07-03 |
西雅图儿童医院（Dba西雅图儿童研究所） |
用于免疫疗法的巨噬细胞的遗传工程
|
|
ES2980794T3
(es)
|
2015-09-15 |
2024-10-03 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
|
|
WO2017053556A1
(en)
|
2015-09-22 |
2017-03-30 |
The Trustees Of The University Of Pennsylvania |
Method of redirecting t cells to treat hiv infection
|
|
AU2016326738B2
(en)
|
2015-09-24 |
2023-08-31 |
Abvitro Llc |
HIV antibody compositions and methods of use
|
|
JP7341661B2
(ja)
|
2015-09-25 |
2023-09-11 |
アブビトロ， エルエルシー |
ネイティブに対合するｔ細胞受容体配列のｔ細胞受容体標的識別のための高スループットプロセス
|
|
WO2017058752A1
(en)
|
2015-09-28 |
2017-04-06 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
|
PE20240096A1
(es)
|
2015-10-02 |
2024-01-18 |
Hoffmann La Roche |
Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
|
|
WO2017059900A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Biontech Cell & Gene Therapies Gmbh |
Antigen receptors and uses thereof
|
|
SG11201803330WA
(en)
|
2015-10-22 |
2018-05-30 |
Juno Therapeutics Gmbh |
Methods for culturing cells and kits and apparatus for same
|
|
US11248238B2
(en)
|
2015-10-22 |
2022-02-15 |
Juno Therapeutics Gmbh |
Methods, kits, agents and apparatuses for transduction
|
|
JP7194020B2
(ja)
|
2015-10-22 |
2022-12-21 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞の培養方法ならびにそのためのキットおよび装置
|
|
DK3368571T5
(da)
|
2015-10-30 |
2024-09-30 |
Univ California |
Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
|
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
ES2873846T5
(en)
*
|
2015-11-19 |
2025-06-23 |
Revitope Ltd |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
|
US10711282B2
(en)
|
2015-11-23 |
2020-07-14 |
Novartis Ag |
Optimized lentiviral transfer vectors and uses thereof
|
|
CN108884140B
(zh)
|
2015-12-03 |
2022-10-25 |
朱诺治疗学股份有限公司 |
修饰的嵌合受体及相关组合物和方法
|
|
CA3007258A1
(en)
|
2015-12-03 |
2017-06-08 |
Mark L. Bonyhadi |
Compositions and methods for reducing immune responses against cell therapies
|
|
EP4012415A3
(en)
|
2015-12-04 |
2022-12-07 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
|
AU2016382512A1
(en)
|
2015-12-30 |
2018-07-12 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
EP3419618A4
(en)
*
|
2016-02-26 |
2019-11-06 |
iCell Gene Therapeutics, LLC |
CHIMERIC ANTIGEN RECEPTORS (CAR) AGAINST HEMATOLOGIC MALIGNOMES, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
EP3430548A1
(en)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
|
US20190355459A1
(en)
|
2016-03-16 |
2019-11-21 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
|
KR20240116832A
(ko)
|
2016-03-17 |
2024-07-30 |
고쿠리츠다이가쿠호우진 야마구치 다이가쿠 |
면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
|
|
US12590321B2
(en)
|
2016-03-19 |
2026-03-31 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
|
|
IL261713B2
(en)
*
|
2016-03-19 |
2023-09-01 |
F1 Oncology Inc |
Methods and preparations for the transfer of lymphocytes and their regulated expansion
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
KR20190021200A
(ko)
|
2016-03-22 |
2019-03-05 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
독성을 예방 또는 경감시키기 위한 조기 개재 방법
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
US20190105348A1
(en)
*
|
2016-04-08 |
2019-04-11 |
Unum Therapeutics Inc. |
Chimeric receptors and uses thereof in immune therapy
|
|
WO2017181101A1
(en)
*
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric alloantigen receptor t cells
|
|
MY209117A
(en)
|
2016-04-15 |
2025-06-23 |
Novartis Ag |
Compositions and methods for selective protein expression
|
|
CN109312304A
(zh)
*
|
2016-04-20 |
2019-02-05 |
弗雷德哈钦森癌症研究中心 |
免疫调节性il2r融合蛋白及其用途
|
|
WO2017186853A1
(en)
*
|
2016-04-27 |
2017-11-02 |
Bcrt Holding Bv |
T cell-based bi-specific immunotherapeutics
|
|
WO2017190096A1
(en)
|
2016-04-29 |
2017-11-02 |
University Of Florida Research Foundation Incorporated |
Chimeric antigen receptors and uses thereof
|
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
CN116850305A
(zh)
|
2016-05-06 |
2023-10-10 |
朱诺治疗学股份有限公司 |
基因工程化细胞及其制备方法
|
|
CN116751298A
(zh)
|
2016-05-13 |
2023-09-15 |
生物蛋白有限公司 |
抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
|
|
AU2017268842B2
(en)
|
2016-05-27 |
2022-08-11 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
|
MX2018014991A
(es)
|
2016-06-03 |
2019-08-29 |
Memorial Sloan Kettering Cancer Center |
Terapias adoptivas de celulas como opciones de tratamiento temprano.
|
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
|
SG11201810640RA
(en)
|
2016-06-08 |
2018-12-28 |
Intrexon Corp |
Cd33 specific chimeric antigen receptors
|
|
JP7114490B2
(ja)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
WO2018005559A1
(en)
|
2016-06-27 |
2018-01-04 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
|
EP3472318B1
(en)
*
|
2016-07-08 |
2023-09-06 |
Exuma Biotech Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
JP7483373B2
(ja)
|
2016-07-29 |
2024-05-15 |
ジュノー セラピューティクス インコーポレイテッド |
複製可能ウイルスの存在または非存在を評価するための方法
|
|
US20240018268A1
(en)
|
2016-07-29 |
2024-01-18 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies against anti-cd19 antibodies
|
|
MA45779A
(fr)
|
2016-07-29 |
2019-06-05 |
Juno Therapeutics Inc |
Polypeptides immunomdulateurs et compositions et procédés associés
|
|
US20190161542A1
(en)
|
2016-08-01 |
2019-05-30 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
NZ750256A
(en)
*
|
2016-08-03 |
2026-02-27 |
Dipersio John F |
Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
|
|
EP4282877A3
(en)
*
|
2016-08-10 |
2024-02-21 |
Legend Biotech Ireland Limited |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
SG11201901642XA
(en)
|
2016-08-26 |
2019-03-28 |
Baylor College Medicine |
Constitutively active cytokine receptors for cell therapy
|
|
JP2019530440A
(ja)
|
2016-09-02 |
2019-10-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物
|
|
EP4282969A3
(en)
*
|
2016-09-02 |
2024-01-31 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
|
BR112019004662A2
(pt)
|
2016-09-12 |
2019-05-28 |
Juno Therapeutics Inc |
conjuntos de sacos de biorreator de perfusão
|
|
CN107841506B
(zh)
*
|
2016-09-20 |
2021-03-16 |
上海恒润达生生物科技有限公司 |
靶向间皮素的嵌合抗原受体及其用途
|
|
CA3037518A1
(en)
*
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
JP2020501512A
(ja)
*
|
2016-09-23 |
2020-01-23 |
ユニバーシティ オブ サザン カリフォルニア |
キメラ抗原受容体およびその組成物ならびにそれらの使用の方法
|
|
EP4353319A3
(en)
|
2016-09-28 |
2024-06-05 |
Atossa Therapeutics, Inc. |
Methods of adoptive cell therapy
|
|
SG11201901959YA
(en)
*
|
2016-09-30 |
2019-04-29 |
Poseida Therapeutics Inc |
Modified stem cell memory t cells, methods of making and methods of using same
|
|
EP3519443A4
(en)
*
|
2016-09-30 |
2020-06-10 |
Baylor College of Medicine |
CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
|
|
US20190119636A1
(en)
|
2017-10-23 |
2019-04-25 |
Poseida Therapeutics, Inc. |
Modified stem cell memory t cells, methods of making and methods of using same
|
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
CA3036745A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
JP2020500031A
(ja)
*
|
2016-10-11 |
2020-01-09 |
ミネルバ バイオテクノロジーズ コーポレーション |
ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用
|
|
BR112019006652A2
(pt)
|
2016-10-13 |
2019-07-02 |
Juno Therapeutics Inc |
métodos e composições para imunoterapia envolvendo moduladores da via metabólica do triptofano
|
|
JP7269167B2
(ja)
*
|
2016-10-14 |
2023-05-08 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
モジュラー四価二重特異性抗体プラットフォーム
|
|
CN110267982B
(zh)
|
2016-10-19 |
2024-02-23 |
斯克利普斯研究所 |
具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
|
|
AU2017355544A1
(en)
|
2016-11-03 |
2019-05-16 |
Juno Therapeutics, Inc. |
Combination therapy of a T cell therapy and a BTK inhibitor
|
|
US20190292246A1
(en)
|
2016-11-03 |
2019-09-26 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia imhibitor
|
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
BR112019011065A2
(pt)
|
2016-12-03 |
2019-10-01 |
Juno Therapeutics Inc |
métodos para determinação da dosagem de células t car
|
|
AU2017368332A1
(en)
|
2016-12-03 |
2019-06-13 |
Juno Therapeutics, Inc. |
Methods for modulation of CAR-T cells
|
|
MA46995A
(fr)
|
2016-12-03 |
2019-10-09 |
Acerta Pharma Bv |
Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
|
|
AU2017370644A1
(en)
|
2016-12-05 |
2019-06-13 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
|
CN110291200B
(zh)
|
2016-12-12 |
2024-05-14 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
|
|
JP7206214B2
(ja)
*
|
2016-12-13 |
2023-01-17 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
US20180100016A1
(en)
*
|
2016-12-22 |
2018-04-12 |
Xiaotong Song |
Use of car-modified human natural killer cells to treat cancer
|
|
AR110424A1
(es)
|
2016-12-23 |
2019-03-27 |
Macrogenics Inc |
Moléculas de unión a adam9 y métodos de uso de las mismas
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
CN108264566B
(zh)
*
|
2016-12-30 |
2021-05-14 |
惠和生物技术(上海)有限公司 |
一种融合抗cd3抗体结构域和t细胞正共刺激分子配体的双特异性分子及其应用
|
|
WO2018132513A1
(en)
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
T cells experessing a chimeric antigen receptor
|
|
WO2018132506A1
(en)
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
Chimeric antigen receptors based on alternative signal 1 domains
|
|
MX2019008227A
(es)
|
2017-01-10 |
2020-08-17 |
Juno Therapeutics Inc |
Analisis epigenetico de terapia celular y metodos relacionados.
|
|
MX2019008538A
(es)
|
2017-01-20 |
2019-11-05 |
Juno Therapeutics Gmbh |
Conjugados de superficie celular y composiciones y métodos celulares relacionados.
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
CN110612119B
(zh)
|
2017-02-07 |
2024-10-29 |
西雅图儿童医院（Dba西雅图儿童研究所） |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
US12163952B2
(en)
|
2017-02-27 |
2024-12-10 |
Juno Therapeutics, Inc. |
Determining toxicity risk in CAR T-cell therapy
|
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための組成物および方法
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
SG11201908271WA
(en)
|
2017-03-14 |
2019-10-30 |
Juno Therapeutics Inc |
Methods for cryogenic storage
|
|
AU2018236450A1
(en)
|
2017-03-16 |
2019-10-03 |
The General Hospital Corporation |
Chimeric antigen receptors targeting CD37
|
|
AU2018236461B2
(en)
|
2017-03-17 |
2025-03-27 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
EP3601346A1
(en)
*
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
EP3601345A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
EP4414380A3
(en)
|
2017-03-31 |
2024-12-04 |
Cellectis SA |
Universal anti-cd22 chimeric antigen receptor engineered immune cells
|
|
AU2018247796A1
(en)
*
|
2017-04-04 |
2019-08-29 |
F. Hoffmann-La Roche Ag |
Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
|
|
EP3607319A1
(en)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
|
CN110709700A
(zh)
|
2017-04-14 |
2020-01-17 |
朱诺治疗学股份有限公司 |
评估细胞表面糖基化的方法
|
|
WO2018195175A1
(en)
|
2017-04-18 |
2018-10-25 |
FUJIFILM Cellular Dynamics, Inc. |
Antigen-specific immune effector cells
|
|
WO2018195339A1
(en)
|
2017-04-19 |
2018-10-25 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
CN108728458B
(zh)
*
|
2017-04-21 |
2021-11-16 |
上海恒润达生生物科技股份有限公司 |
靶向mesothelin的嵌合抗原受体并联合表达IL-15的方法和用途
|
|
KR20190140943A
(ko)
*
|
2017-04-24 |
2019-12-20 |
메모리얼 슬로안 케터링 캔서 센터 |
항-cd33 항체 제제
|
|
JP7339160B2
(ja)
|
2017-04-27 |
2023-09-05 |
ジュノ セラピューティクス ゲーエムベーハー |
オリゴマー粒子試薬およびその使用方法
|
|
US20200078404A1
(en)
|
2017-05-01 |
2020-03-12 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
|
AU2018269194B2
(en)
|
2017-05-15 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
|
CN111201438A
(zh)
|
2017-06-02 |
2020-05-26 |
朱诺治疗学股份有限公司 |
与和细胞疗法相关的毒性有关的制品和方法
|
|
AU2018275894B2
(en)
|
2017-06-02 |
2025-04-24 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
EP3635132A4
(en)
*
|
2017-06-07 |
2021-05-26 |
Intrexon Corporation |
EXPRESSION OF NOVEL CELL MARKERS
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
HRP20210567T1
(hr)
|
2017-06-20 |
2021-09-03 |
Institut Curie |
Imune stanice kojima nedostaje suv39hl
|
|
CA3287539A1
(en)
|
2017-06-21 |
2026-03-02 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
|
|
WO2018237325A1
(en)
*
|
2017-06-22 |
2018-12-27 |
University Of Southern California |
Combination cancer therapy using chimeric antigen receptor engineered natural killer cells as chemotherapeutic drug carriers
|
|
CA3068286A1
(en)
|
2017-06-22 |
2018-12-27 |
Board Of Regents, The University Of Texas System |
Methods for producing regulatory immune cells and uses thereof
|
|
EP3644721A1
(en)
|
2017-06-29 |
2020-05-06 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
|
WO2019018402A2
(en)
*
|
2017-07-17 |
2019-01-24 |
Janssen Biotech, Inc. |
ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
|
|
WO2019014891A1
(zh)
*
|
2017-07-20 |
2019-01-24 |
深圳普瑞金生物药业有限公司 |
一种用于治疗肿瘤的egfr单域抗体cart及其应用
|
|
SG11202000503QA
(en)
|
2017-07-20 |
2020-02-27 |
Aptevo Res & Development Llc |
Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
|
|
BR112020001719A2
(pt)
|
2017-07-29 |
2020-07-21 |
Juno Therapeutics Inc |
reagentes para expansão de células que expressam receptores recombinantes
|
|
US10442867B2
(en)
|
2017-07-31 |
2019-10-15 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
|
AU2018313950A1
(en)
|
2017-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
|
CN111263641B
(zh)
|
2017-08-09 |
2025-10-31 |
朱诺治疗学股份有限公司 |
用于制备基因工程化细胞的方法和组合物
|
|
CN109423495A
(zh)
*
|
2017-08-24 |
2019-03-05 |
上海恒润达生生物科技有限公司 |
一种双靶向嵌合抗原受体及其用途
|
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
|
EP3679370A1
(en)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
|
US20200268795A1
(en)
*
|
2017-09-22 |
2020-08-27 |
The Regents Of The University Of California |
Interferon-gamma attenuates anti-tumor immune response to checkpoint blockade
|
|
BR112020006643A2
(pt)
|
2017-10-03 |
2020-09-24 |
Juno Therapeutics Inc |
moléculas de ligação específica ao hpv
|
|
US20200239544A1
(en)
*
|
2017-10-03 |
2020-07-30 |
Precision Biosciences, Inc. |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
|
KR102790597B1
(ko)
|
2017-10-10 |
2025-04-07 |
고쿠리츠다이가쿠호우진 야마구치 다이가쿠 |
메모리 기능을 갖는 t세포 또는 b세포의 증강제, 악성 종양 재발 억제제 및 t세포 또는 b세포에 메모리 기능을 유도하는 유도제
|
|
CN119930795A
(zh)
|
2017-10-12 |
2025-05-06 |
得克萨斯大学体系董事会 |
用于免疫疗法的t细胞受体
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
JP7585034B2
(ja)
|
2017-10-18 |
2024-11-18 |
ノバルティス アーゲー |
選択的タンパク質分解のための組成物及び方法
|
|
US10329543B2
(en)
|
2017-10-23 |
2019-06-25 |
Poseida Therapeutics, Inc. |
Modified stem cell memory T cells, methods of making and methods of using same
|
|
MX2020004229A
(es)
|
2017-10-25 |
2020-07-22 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
|
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
EP3703675A4
(en)
|
2017-10-30 |
2021-06-16 |
Neuropore Therapies, Inc. |
SUBSTITUTED PHENYLSULFONYLPHÉNYLTRIAZOLETHIONES AND ASSOCIATED USES
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
EP3704230B1
(en)
|
2017-11-01 |
2024-10-23 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
|
AU2018358067A1
(en)
|
2017-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
|
SG11202003657VA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Process for producing a t cell composition
|
|
JP7447006B2
(ja)
|
2017-11-01 |
2024-03-11 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
BR112020008478A2
(pt)
|
2017-11-01 |
2020-10-20 |
Editas Medicine, Inc. |
métodos, composições e componentes para edição de crispr-cas9 de tgfbr2 em células t para imunota-rapia
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
JP2021502077A
(ja)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン，インコーポレイテッド |
免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
|
|
SG11202003427XA
(en)
|
2017-11-06 |
2020-05-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
CN111683962B
(zh)
*
|
2017-11-10 |
2025-05-16 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向肿瘤抗原的嵌合抗原受体
|
|
JP2021502094A
(ja)
|
2017-11-10 |
2021-01-28 |
ジュノー セラピューティクス インコーポレイテッド |
閉鎖系極低温容器
|
|
CN108034669B
(zh)
*
|
2017-11-17 |
2021-07-30 |
山东兴瑞生物科技有限公司 |
一种抗vegf基因、及利用其修饰的t细胞、制备方法和应用
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
GB201719557D0
(en)
*
|
2017-11-24 |
2018-01-10 |
Autolus Ltd |
Polypeptide
|
|
US20210198372A1
(en)
|
2017-12-01 |
2021-07-01 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
|
JP7433230B2
(ja)
|
2017-12-08 |
2024-02-19 |
ジュノー セラピューティクス インコーポレイテッド |
細胞を培養するための無血清培地配合物およびその使用の方法
|
|
WO2019113557A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
|
CA3084446A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
MA51428A
(fr)
*
|
2017-12-22 |
2020-11-04 |
Bluebird Bio Inc |
Récepteur d'antigène chimérique multivalent
|
|
CA3083779A1
(en)
|
2017-12-22 |
2019-06-27 |
Fate Therapeutics, Inc. |
Enhanced immune effector cells and use thereof
|
|
GB201721802D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Almac Discovery Ltd |
Ror1-specific antigen binding molecules
|
|
WO2019127215A1
(en)
*
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
|
JP2021508468A
(ja)
*
|
2017-12-29 |
2021-03-11 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
メディトープ対応ｔ細胞
|
|
US12491153B2
(en)
|
2018-01-03 |
2025-12-09 |
Qu Biologics Inc. |
Innate targeting of adoptive cellular therapies
|
|
US11919937B2
(en)
|
2018-01-09 |
2024-03-05 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
|
CA3087476A1
(en)
*
|
2018-01-10 |
2019-07-18 |
The General Hospital Corporation |
Immune cells expressing a chimeric antigen receptor
|
|
US10561686B2
(en)
|
2018-01-12 |
2020-02-18 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
CN108285486A
(zh)
*
|
2018-01-15 |
2018-07-17 |
浙江阿思科力生物科技有限公司 |
以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
JP7549303B2
(ja)
|
2018-01-22 |
2024-09-11 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞の使用方法
|
|
KR102115236B1
(ko)
*
|
2018-01-29 |
2020-05-27 |
(주)에스엠티바이오 |
췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
|
|
JP7383620B2
(ja)
|
2018-01-31 |
2023-11-20 |
セルジーン コーポレイション |
養子細胞療法およびチェックポイント阻害剤を使用する併用療法
|
|
US11535903B2
(en)
|
2018-01-31 |
2022-12-27 |
Juno Therapeutics, Inc. |
Methods and reagents for assessing the presence or absence of replication competent virus
|
|
SG11202007426XA
(en)
|
2018-02-06 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
CN108219004A
(zh)
*
|
2018-02-08 |
2018-06-29 |
吉林省拓华生物科技有限公司 |
双特异嵌合抗原受体修饰的t细胞、其制备方法及用途
|
|
CN111886028A
(zh)
|
2018-02-09 |
2020-11-03 |
达特茅斯大学理事会 |
用于治疗神经退行性疾病和障碍的嵌合抗原受体
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
|
SG11202008926RA
(en)
|
2018-03-14 |
2020-10-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
|
|
JP7575271B2
(ja)
|
2018-03-29 |
2024-10-29 |
フェイト セラピューティクス，インコーポレイテッド |
操作された免疫エフェクター細胞およびその使用
|
|
CN108251392B
(zh)
*
|
2018-03-30 |
2021-04-20 |
广东溢多利生物科技股份有限公司 |
提高比活和热稳定性的葡萄糖氧化酶突变体及其编码基因和应用
|
|
AU2019249209A1
(en)
|
2018-04-05 |
2020-10-15 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
|
CA3094468A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
|
CA3095757A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating glioblastomas
|
|
CA3096202A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating egfrviii expressing glioblastomas
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
CN108715616A
(zh)
*
|
2018-04-27 |
2018-10-30 |
上海恒润达生生物科技有限公司 |
靶向人源化间皮素的嵌合抗原受体方法和用途
|
|
CA3091490A1
(en)
|
2018-04-27 |
2019-10-31 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
US20210121466A1
(en)
|
2018-05-03 |
2021-04-29 |
Juno Therapeutics, Inc. |
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
US20210230289A1
(en)
|
2018-06-12 |
2021-07-29 |
The Regents Of The University Of California |
Single-chain bispecific chimeric antigen receptors for the treatment of cancer
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
CN112533629A
(zh)
|
2018-06-19 |
2021-03-19 |
阿尔莫生物科技股份有限公司 |
结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
|
|
CN110615842B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含共刺激受体的嵌合抗原受体及应用
|
|
WO2019246546A1
(en)
*
|
2018-06-22 |
2019-12-26 |
The General Hospital Corporation |
Chimeric antigen receptors targeting cd37 and cd19
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US20210275589A1
(en)
*
|
2018-07-13 |
2021-09-09 |
Nanjing Legend Biotech Co. Ltd. |
Co-receptor systems for treating infectious diseases
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
EA202190469A1
(ru)
|
2018-08-09 |
2021-06-28 |
Джуно Терапьютикс, Инк. |
Способы оценки интегрированных нуклеиновых кислот
|
|
CN113474450A
(zh)
|
2018-08-09 |
2021-10-01 |
朱诺治疗学股份有限公司 |
产生工程化细胞的方法以及所述工程化细胞的组合物
|
|
WO2020037120A1
(en)
*
|
2018-08-16 |
2020-02-20 |
Nantbio, Inc. |
Il7-il15 txm compositions and methods
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
MX2021002574A
(es)
|
2018-09-11 |
2021-06-08 |
Juno Therapeutics Inc |
Metodos para el analisis por espectrometria de masas de composiciones de celulas modificadas.
|
|
CN109293781A
(zh)
*
|
2018-09-12 |
2019-02-01 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用
|
|
WO2020061796A1
(en)
*
|
2018-09-26 |
2020-04-02 |
Hrain Biotechnology Co., Ltd. |
Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof
|
|
EP3632460A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
CA3112310C
(en)
|
2018-10-05 |
2025-05-06 |
Universitat Fur Bodenkultur Wien |
CHIMERIC ANTIGEN RECEPTOR GROUP (CAR)
|
|
US12600776B2
(en)
|
2018-10-19 |
2026-04-14 |
Cartexell Inc. |
Anti-L1CAM antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
|
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
|
EP3874024A1
(en)
|
2018-10-31 |
2021-09-08 |
Juno Therapeutics GmbH |
Methods for selection and stimulation of cells and apparatus for same
|
|
KR20210113169A
(ko)
|
2018-11-01 |
2021-09-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
|
|
SG11202104524YA
(en)
|
2018-11-01 |
2021-05-28 |
Gracell Biotechnologies Shanghai Co Ltd |
Compositions and methods for t cell engineering
|
|
EP3877054B1
(en)
|
2018-11-06 |
2023-11-01 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
|
US12466892B2
(en)
|
2018-11-08 |
2025-11-11 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
WO2020097403A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
|
KR20210104713A
(ko)
|
2018-11-16 |
2021-08-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
|
|
EP3883955A1
(en)
|
2018-11-19 |
2021-09-29 |
Board of Regents, The University of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
US12590148B2
(en)
|
2018-11-26 |
2026-03-31 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
WO2020113029A2
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
MX2021006393A
(es)
|
2018-11-29 |
2021-10-13 |
Univ Texas |
Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
|
|
PL3886894T3
(pl)
|
2018-11-30 |
2024-07-01 |
Juno Therapeutics, Inc. |
Metody dawkowania i leczenia nowotworów b-komórkowych w adoptywnej terapii komórkowej
|
|
WO2020113224A2
(en)
*
|
2018-11-30 |
2020-06-04 |
Dana-Farber Cancer Institute, Inc. |
Chimeric antigen receptor factories and methods of use thereof
|
|
PL3886875T3
(pl)
|
2018-11-30 |
2024-09-09 |
Juno Therapeutics, Inc. |
Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej
|
|
KR102943217B1
(ko)
|
2018-12-02 |
2026-03-25 |
페이트 세러퓨틱스, 인코포레이티드 |
향상된 iPSC 유래 효과기 세포를 사용한 면역요법
|
|
KR102840400B1
(ko)
*
|
2018-12-12 |
2025-08-04 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
MA54540A
(fr)
*
|
2018-12-19 |
2021-10-27 |
Regeneron Pharma |
Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
EP3908613A4
(en)
*
|
2019-01-07 |
2022-10-19 |
Celluris Participações Ltda. |
BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA
|
|
EP3914719A4
(en)
|
2019-01-24 |
2023-04-05 |
Valorisation-HSJ, Limited Partnership |
Cell-specific transcriptional regulatory sequences and uses thereof
|
|
CA3123303A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
AU2020219246A1
(en)
*
|
2019-02-08 |
2021-08-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric cytokine receptors
|
|
CN111544585B
(zh)
*
|
2019-02-11 |
2024-12-27 |
北京卡替医疗技术有限公司 |
一种可助推免疫细胞在体内扩增的佐剂
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
AU2020221324A1
(en)
|
2019-02-15 |
2021-09-02 |
University Of Southern California |
Lym-1 and Lym-2 antibody compositions and improved CAR constructs
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20230348556A1
(en)
*
|
2019-02-21 |
2023-11-02 |
Arbele Limited |
Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
|
|
US20220133795A1
(en)
|
2019-03-01 |
2022-05-05 |
Iovance Biotherapeutics, Inc. |
Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
WO2020183131A1
(en)
|
2019-03-08 |
2020-09-17 |
Autolus Limited |
Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
|
|
ES2911273T3
(es)
*
|
2019-03-19 |
2022-05-18 |
Miltenyi Biotec Bv & Co Kg |
Método para proporcionar células personalizadas con receptores de antígeno quimérico (CAR)
|
|
CN120172958A
(zh)
|
2019-04-12 |
2025-06-20 |
C4医药公司 |
Ikaros和aiolos的三环降解物
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EP3962527A4
(en)
|
2019-04-30 |
2023-11-01 |
Senti Biosciences, Inc. |
CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
|
|
EP3962519A1
(en)
|
2019-05-01 |
2022-03-09 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
|
CA3139319A1
(en)
*
|
2019-05-07 |
2020-11-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhancement of polypeptides and chimeric antigen receptors via hinge domains
|
|
CA3139346A1
(en)
|
2019-05-07 |
2020-11-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Engineered immune cell targeting bcma and use thereof
|
|
CN113840912A
(zh)
*
|
2019-05-16 |
2021-12-24 |
南京传奇生物科技有限公司 |
包含识别分子的工程化免疫细胞
|
|
MX2021015125A
(es)
|
2019-06-07 |
2022-04-06 |
Juno Therapeutics Inc |
Cultivo automatizado de celulas t.
|
|
EP3983006A1
(en)
|
2019-06-12 |
2022-04-20 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
|
CN114222763A
(zh)
*
|
2019-06-19 |
2022-03-22 |
尤利乌斯·马克西米利安维尔茨堡大学 |
在嵌合抗原受体设计中实现的超模块化IgG3间隔区结构域和多功能位点
|
|
BR112022000641A2
(pt)
|
2019-07-17 |
2022-03-29 |
Fate Therapeutics Inc |
Modificação genética de célula efetora imune e uso da mesma
|
|
US20220251572A1
(en)
|
2019-07-23 |
2022-08-11 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
CN112390891B
(zh)
*
|
2019-08-14 |
2022-06-03 |
苏州方德门达新药开发有限公司 |
嵌合抗原受体及其构建方法和应用
|
|
JP2022545467A
(ja)
|
2019-08-22 |
2022-10-27 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
|
|
EP4022637A2
(en)
|
2019-08-30 |
2022-07-06 |
Juno Therapeutics, Inc. |
Machine learning methods for classifying cells
|
|
EP4025244A1
(en)
|
2019-09-02 |
2022-07-13 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
|
JP7831937B2
(ja)
|
2019-09-03 |
2026-03-17 |
クリエイト・メディシンズ，インコーポレーテッド |
ゲノム組込みのための方法および組成物
|
|
CA3153700A1
(en)
|
2019-09-09 |
2021-03-18 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
|
US20240082403A1
(en)
*
|
2019-10-11 |
2024-03-14 |
The Regents Of The University Of California |
Chimeric Antigen Receptors against Human Cytomegalovirus
|
|
WO2021078910A1
(en)
|
2019-10-22 |
2021-04-29 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
|
WO2021084050A1
(en)
|
2019-10-30 |
2021-05-06 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
|
IL292667B1
(en)
|
2019-11-07 |
2026-02-01 |
Juno Therapeutics Inc |
Combination of T-cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-3,l-dihydro-isoindol-2-yl]-piperidine-6,2-dione
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
CN115916817A
(zh)
|
2019-12-06 |
2023-04-04 |
朱诺治疗学股份有限公司 |
针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
|
|
KR20220122656A
(ko)
|
2019-12-06 |
2022-09-02 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법
|
|
IL293393A
(en)
|
2019-12-06 |
2022-07-01 |
Juno Therapeutics Inc |
Cell therapy-related toxicity and response-related methods for the treatment of b-cell malignancies
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
JP7088902B2
(ja)
*
|
2019-12-27 |
2022-06-21 |
クレージュ メディカル カンパニー，リミテッド |
キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
|
|
CA3166420A1
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Il2 orthologs and methods of use
|
|
AU2021211713A1
(en)
|
2020-01-23 |
2022-08-25 |
The Children's Medical Center Corporation |
Stroma-free T cell differentiation from human pluripotent stem cells
|
|
JP2023513434A
(ja)
|
2020-01-24 |
2023-03-31 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法における投与ならびに濾胞性リンパ腫および辺縁帯リンパ腫の処置のための方法
|
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
|
AU2021217003A1
(en)
|
2020-02-04 |
2022-09-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Anti-dinitrophenol chimeric antigen receptors
|
|
IL295384B1
(en)
|
2020-02-12 |
2026-04-01 |
Juno Therapeutics Inc |
T-cell preparations with chimeric antigen receptor directed against CD19 and methods and uses thereof
|
|
IL295381B1
(en)
|
2020-02-12 |
2026-04-01 |
Juno Therapeutics Inc |
BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
|
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
EP4081552A4
(en)
*
|
2020-02-17 |
2024-01-24 |
University of Virginia Patent Foundation |
Car t cells targeting the integrin alphav beta3 exhibit robust anti-tumor responses against gliomas and other solid tumor malignancies
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
IL296511A
(en)
*
|
2020-03-20 |
2022-11-01 |
Lyell Immunopharma Inc |
Novel recombinant cell surface markers
|
|
WO2021202799A2
(en)
|
2020-03-31 |
2021-10-07 |
Fred Hutchinson Cancer Research Center |
Chimeric antigen receptors targeting cd33
|
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US20230348854A1
(en)
*
|
2020-05-08 |
2023-11-02 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Chimeric antigen receptors (cars) targeting natural killer cells
|
|
WO2021228999A1
(en)
|
2020-05-12 |
2021-11-18 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
|
WO2021231661A2
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
JP7727662B2
(ja)
|
2020-05-13 |
2025-08-21 |
ジュノー セラピューティクス インコーポレイテッド |
臨床応答に関連する特徴量の特定方法およびその使用
|
|
AU2021275239A1
(en)
|
2020-05-21 |
2022-12-15 |
Board Of Regents, The University Of Texas System |
T cell receptors with VGLL1 specificity and uses thereof
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
US20230203168A1
(en)
*
|
2020-06-02 |
2023-06-29 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
AU2021292695A1
(en)
|
2020-06-19 |
2023-02-02 |
Fate Therapeutics, Inc. |
Combining iPSC-derived effector cell types for immunotherapy use
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
CA3190266A1
(en)
|
2020-07-30 |
2022-02-03 |
Institut Curie |
Immune cells defective for socs1
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2022029660A1
(en)
|
2020-08-05 |
2022-02-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
|
JP2023538303A
(ja)
|
2020-08-13 |
2023-09-07 |
イェール ユニバーシティー |
所望の表現型を有するｃａｒ ｔ細胞の操作および選択のための組成物および方法
|
|
WO2022036495A1
(en)
|
2020-08-17 |
2022-02-24 |
Utc Therapeutics Inc. |
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
|
|
KR20230054391A
(ko)
|
2020-08-21 |
2023-04-24 |
12343096 캐나다 인코포레이티드 |
모듈러 조립 수용체 및 그의 용도
|
|
CA3193009A1
(en)
*
|
2020-08-26 |
2022-03-03 |
The Regents Of The University Of California |
Methods and compositions for treating glioblastoma
|
|
EP4232071A4
(en)
|
2020-10-23 |
2024-08-28 |
Asher Biotherapeutics, Inc. |
FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
|
|
JP2023548467A
(ja)
*
|
2020-11-04 |
2023-11-17 |
フェイト セラピューティクス，インコーポレイティド |
操作されたｉＰＳＣ及び持続性免疫エフェクター細胞
|
|
CA3201499A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
AU2021392032A1
(en)
|
2020-12-03 |
2023-06-22 |
Century Therapeutics, Inc. |
Genetically engineered cells and uses thereof
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
EP4274901A1
(en)
|
2021-01-11 |
2023-11-15 |
Sana Biotechnology, Inc. |
Use of cd8-targeted viral vectors
|
|
CN118703444A
(zh)
*
|
2021-01-22 |
2024-09-27 |
南京助天中科科技发展有限公司 |
一种嵌合抗原受体改造的nk细胞及其制备方法与应用
|
|
CN114907485B
(zh)
*
|
2021-02-08 |
2024-04-26 |
浙江大学 |
一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
|
|
CA3207861A1
(en)
*
|
2021-02-11 |
2022-08-18 |
Carl H. June |
Ccr4-targeting chimeric antigen receptor cell therapy
|
|
AU2022227686A1
(en)
|
2021-02-25 |
2023-07-27 |
Lyell Immunopharma, Inc. |
Ror1 targeting chimeric antigen receptor
|
|
JP2024509853A
(ja)
|
2021-03-03 |
2024-03-05 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
|
|
US20250041412A1
(en)
|
2021-03-11 |
2025-02-06 |
Institut Curie |
Transmembrane neoantigenic peptides
|
|
WO2022189639A1
(en)
|
2021-03-11 |
2022-09-15 |
Mnemo Therapeutics |
Tumor neoantigenic peptides and uses thereof
|
|
EP4304632A2
(en)
|
2021-03-11 |
2024-01-17 |
Mnemo Therapeutics |
Tumor neoantigenic peptides
|
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
|
CN117321200A
(zh)
|
2021-03-22 |
2023-12-29 |
朱诺治疗学股份有限公司 |
评估病毒载体颗粒效力的方法
|
|
CN115109754B
(zh)
*
|
2021-03-23 |
2025-04-01 |
复星凯瑞(上海)生物科技有限公司 |
抗EGFR和cMet双特异性嵌合抗原受体及其应用
|
|
AU2022252220A1
(en)
|
2021-03-29 |
2023-10-12 |
Juno Therapeutics, Inc. |
Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
|
|
US20240181052A1
(en)
|
2021-03-29 |
2024-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CN113735978B
(zh)
*
|
2021-04-22 |
2023-06-30 |
河北森朗生物科技有限公司 |
靶向cd19的嵌合抗原受体、制备方法及其应用
|
|
EP4326293A4
(en)
|
2021-04-22 |
2025-03-12 |
Baylor College of Medicine |
METHODS FOR MODIFYING IMMUNE CELLS HAVING REDUCED FRATRICIDAL ACTIVITY
|
|
EP4330381A1
(en)
|
2021-04-27 |
2024-03-06 |
Novartis AG |
Viral vector production system
|
|
US20250283037A1
(en)
|
2021-05-06 |
2025-09-11 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
|
AU2022272235A1
(en)
|
2021-05-11 |
2023-12-21 |
Create Medicines, Inc. |
Methods and compositions for genomic integration
|
|
CA3173810A1
(en)
|
2021-06-01 |
2022-12-01 |
Andreas Bader |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
WO2023015217A1
(en)
|
2021-08-04 |
2023-02-09 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
US20250114452A1
(en)
|
2021-08-04 |
2025-04-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
|
EP4384549A1
(en)
*
|
2021-08-12 |
2024-06-19 |
Cellogen Therapeutics Pvt. Ltd. |
Chimeric antigen receptors (car) for b cell malignancies
|
|
CN118056012B
(zh)
*
|
2021-08-24 |
2025-05-30 |
赛斯尔擎生物技术（上海）有限公司 |
一种修饰细胞的方法
|
|
GB202112923D0
(en)
|
2021-09-10 |
2021-10-27 |
Ucl Business Ltd |
Binding domain
|
|
US20250009879A1
(en)
*
|
2021-11-22 |
2025-01-09 |
The Asan Foundation |
Natural killer cell-specific chimeric antigen receptor and use thereof
|
|
US20250354167A1
(en)
|
2021-12-09 |
2025-11-20 |
Zygosity Limited |
Vector
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
EP4456910A1
(en)
|
2021-12-28 |
2024-11-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
|
US20250115916A1
(en)
|
2022-01-21 |
2025-04-10 |
Mnemo Therapeutics |
Modulation of suv39h1 expression by rnas
|
|
JP2025504002A
(ja)
|
2022-01-28 |
2025-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
細胞組成物を製造する方法
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
US20250135002A1
(en)
*
|
2022-02-04 |
2025-05-01 |
Duke University |
Compositions for and method of effecting tumor cell death
|
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
|
US20250195573A1
(en)
|
2022-03-18 |
2025-06-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetically engineered t-cell co-receptors and methods of use thereof
|
|
JP2025510795A
(ja)
|
2022-03-24 |
2025-04-15 |
アンスティテュ・クリー |
神経膠芽腫における腫瘍転位因子由来のネオ抗原ペプチドを標的化する免疫療法
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
WO2023196933A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
|
CA3247010A1
(en)
|
2022-04-08 |
2023-10-12 |
Ono Pharmaceutical Co., Ltd. |
CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING
|
|
EP4504914A4
(en)
|
2022-04-08 |
2026-04-29 |
Fate Therapeutics Inc |
Cells having solid tumor targeting backbone and use thereof
|
|
EP4514382A1
(en)
|
2022-04-28 |
2025-03-05 |
Musc Foundation for Research Development |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
EP4543923A1
(en)
|
2022-06-22 |
2025-04-30 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
US20250382640A1
(en)
|
2022-06-29 |
2025-12-18 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
CA3264572A1
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
DELTA-TYPE CHIMERICAL ANTIBODIES AND ANTIGENIC RECEPTORS (DLL3)
|
|
CN120152717A
(zh)
|
2022-09-08 |
2025-06-13 |
朱诺治疗学股份有限公司 |
T细胞疗法和连续或间歇dgk抑制剂给药的组合
|
|
CN117305248A
(zh)
*
|
2022-09-09 |
2023-12-29 |
复星凯特生物科技有限公司 |
抗EGFR和cMet双特异性嵌合抗原受体及其应用
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
CN120112650A
(zh)
|
2022-10-26 |
2025-06-06 |
诺华股份有限公司 |
慢病毒配制品
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
CN121100267A
(zh)
|
2022-12-09 |
2025-12-09 |
朱诺治疗学股份有限公司 |
使用全息成像预测细胞表型的机器学习方法
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
KR20260005874A
(ko)
|
2023-02-28 |
2026-01-12 |
주노 쎄러퓨티크스 인코퍼레이티드 |
전신 자가면역 질환을 치료하기 위한 세포 요법
|
|
EP4676499A2
(en)
*
|
2023-03-10 |
2026-01-14 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Methods and compositions for cellular immunotherapy- fib4
|
|
EP4676945A2
(en)
*
|
2023-03-10 |
2026-01-14 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Methods and compositions for cellular immunotherapy - fib2
|
|
WO2024192134A1
(en)
*
|
2023-03-13 |
2024-09-19 |
Immpact Bio Usa, Inc. |
Bispecific cars for the treatment of lupus and autoimmune diseases
|
|
CA3278900A1
(en)
|
2023-03-31 |
2024-10-03 |
AbelZeta Inc. |
BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
EP4698665A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
EP4698666A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
WO2024226829A2
(en)
|
2023-04-26 |
2024-10-31 |
Yale University |
Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
|
|
WO2024226858A1
(en)
|
2023-04-26 |
2024-10-31 |
Juno Therapeutics, Inc. |
Methods for viral vector manufacturing
|
|
CN121464348A
(zh)
|
2023-05-23 |
2026-02-03 |
朱诺治疗学股份有限公司 |
T细胞的激活标记物和评估t细胞激活的方法
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
EP4520334A1
(en)
|
2023-09-07 |
2025-03-12 |
Mnemo Therapeutics |
Methods and compositions for improving immune response
|
|
WO2025052001A1
(en)
|
2023-09-07 |
2025-03-13 |
Mnemo Therapeutics |
Methods and compositions for improving immune response
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025082603A1
(en)
|
2023-10-18 |
2025-04-24 |
Institut Curie |
Engineered immune cells overexpressing cd74 molecule
|
|
WO2025096975A1
(en)
|
2023-11-02 |
2025-05-08 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods of enhancing immune cell therapies by runx2 modulation
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025176853A1
(en)
|
2024-02-22 |
2025-08-28 |
Miltenyi Biotec B.V. & Co. KG |
Cd4- or cd8-targeted retroviral vector particles for generation of cells expressing a bispecific chimeric antigen receptor
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|
|
WO2025231185A1
(en)
|
2024-05-01 |
2025-11-06 |
Legend Biotech Ireland Limited |
Viral glycoprotein variants and uses thereof
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
NL2037929B1
(en)
|
2024-06-11 |
2026-01-12 |
Prinses Maxima Centrum Voor Kinderoncologie B V |
Brain Organoid
|
|
WO2026020055A2
(en)
|
2024-07-18 |
2026-01-22 |
Juno Therapeutics, Inc. |
Methods for assessing exosomes in a cell composition and related uses
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|
|
WO2026062222A1
(en)
|
2024-09-20 |
2026-03-26 |
Institut Curie |
Novel protein isoforms and uses
|